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Objective. To investigate the expression and tissue distribution of Th9-related cytokines in patients with psoriatic arthritis (PsA).
Methods. Quantitative gene expression analysis of Th1, Th17, and Th9 cytokines was performed in intestinal biopsy samples obtained from patients with PsA, HLA2B272positive patients with ankylosing spondylitis (AS), patients with Crohn's disease (CD), and healthy controls. Expression and tissue distribution of interleukin-23 (IL-23), IL-17, IL-22, IL-9, and IL-9 receptor (IL-9R) were evaluated by immunohistochemistry and confocal microscopy. Flow cytometry was used to study the frequency of Th9 cells among peripheral blood, lamina propria, and synovial fluid mononuclear cells. The functional relevance of IL-9R expression on epithelial cells was assessed in functional in vitro studies. Th9 cells in synovial tissue from patients with PsA were also studied.
Results. Subclinical gut inflammation in PsA patients was characterized by a clear Th17 and Th22, but not Th1, polarized immune response. Unlike AS and CD, a strong and significant up-regulation of IL-9 was observed in PsA gut, especially among infiltrating mononuclear cells, high endothelial venules, and Paneth cells. IL-92positive mononuclear cells were demonstrated to be in large part Th9 cells. IL-9 overexpression was accompanied by significant Paneth cell hyperplasia. Paneth cells strongly overexpressed IL-9R, and stimulation of epithelial cells, isolated from PsA patients, with IL-9 resulted in overexpression of a-defensin 5 and IL-23p19. Peripheral and synovial expansion of a4b71 Th9 cells was also observed in patients with PsA. Increased expression of IL-9 and IL-9R was also found in synovial tissue.
Conclusion. Strong IL-9/Th9 polarization seems to be the predominant immunologic signature in patients in PsA.
(IL-23)/Th17 response (2) (3) (4) . Recently IL-9, a member of the IL-2 cytokine family that is secreted by naive CD41 T cells in response to transforming growth factor b (5), has been demonstrated to be involved in the pathogenesis of several autoimmune diseases, including psoriasis (6) (7) (8) (9) . In the present study we aimed to characterize the subclinical gut inflammation of PsA, to investigate the expression and tissue distribution of IL-9/ Th9-related molecules, and to evaluate the effect of tumor necrosis factor inhibitor (TNFi) and ustekinumab therapy on circulating Th9 cells.
PATIENTS AND METHODS
Patients. Intestinal biopsy specimens were obtained from 25 patients with PsA fulfilling the criteria of the Classification of Psoriatic Arthritis Study Group (10) (11 with predominant axial involvement) and from 15 patients with HLA-B27-positive ankylosing spondylitis (AS) fulfilling the New York criteria (11) , without gastrointestinal symptoms. Ten patients with CD and 20 healthy controls who underwent ileocolonoscopy for routine clinical evaluation were also included in the study. Synovial tissue samples were also obtained from an additional 5 PsA patients with active disease at the time of sample collection and from 5 patients with osteoarthritis (OA) (12) . Baseline characteristics of the patients and controls are shown in Supplementary Table 1 (on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.39649/abstract). Disease activity in patients with PsA with axial involvement and patients with AS was assessed with the Bath Ankylosing Spondylitis Disease Activity Score (BAS-DAI) (13); the 28-joint Disease Activity Score (DAS28) (14) was used to evaluate disease activity in patients with PsA and peripheral disease, and the Crohn's Disease Activity Index (CDAI) (15) was used to assess patients with CD. The severity of psoriasis was evaluated by the Psoriasis Area and Severity Index (PASI) (16) . Collection of samples was approved by the local ethics committee and the University of Palermo Institutional Review Board, and informed consent was obtained from all patients and controls.
Histomorphologic grading and immunohistochemistry analysis. Biopsy specimens were evaluated by 2 experienced pathologists with expertise in inflammatory bowel diseases (AR and AC) who were blinded with regard to clinical data. Interrater agreement between the 2 pathologists, calculated with Cohen's kappa coefficient, was 0.85.
Gut specimens from patients with PsA and AS were assessed histologically for the presence of inflammation and classified according to the stage of histologic severity, as follows (17): stage 0 5 normal histopathologic findings; stage 1 5 lymphoid hyperplasia with increased inflammatory cell content in the lamina propria without evidence of cryptitis or epithelial abnormalities; stage 2 5 diffuse increase of inflammatory cells in the lamina propria with crypt distortion, hyperplasia of crypt cell epithelium, infiltration of neutrophils, and crypt abscesses; stage 3 5 ulcerations with or without epithelioid granulomas. Lymphoid follicles were identified using CD3/ CD19/CD21 immunostaining.
The degree of inflammation was also evaluated in synovial tissue obtained from 5 patients with PsA and, as controls, from 5 patients with end-stage OA who were undergoing knee joint replacement surgery. The grade of tissue inflammation was also assessed by evaluating the number of CD31, CD191, and CD681 cells. Immunohistochemistry analysis was performed as previously described (18) ; antibodies used are listed in Supplementary Table 2 (http://onlinelibrary.wiley. com/doi/10.1002/art.39649/abstract). The number of immunoreactive cells and lymphoid follicles was determined by counting the reactive cells/lymphoid follicles seen on photomicrographs obtained from 3 randomly and independently selected highpower fields (hpf).
To specifically address the nature of IL-9-producing cells, double staining for Th2 (IL-4/IL-9), Th17 (IL-9/IL-17), and Paneth cells (IL-9/a-defensin 5) and triple staining for Th9 cells (CD4/IL-9/PU.1) were performed on paraffinembedded synovial and ileal sections. Sections were treated with fluorescein isothiocyanate-, rhodamine red-, or Cy5-conjugated anti-mouse or anti-rabbit antibodies (Invitrogen) plus RNase (200 ng/ml) and counterstained using TOTO-3 iodide (642/660; Invitrogen) or DAPI (Life Technologies). Confocal microscopy was used to assess fluorescence staining.
RNA extraction and quantitative TaqMan real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis of ileal biopsy specimens. Total RNA was extracted using a Qiagen RNeasy Mini kit, with on-column DNase I digestion. A total of 1 mg of RNA was reverse-transcribed to complementary DNA using a ThermoScript First-Strand cDNA Synthesis kit (Invitrogen). For quantitative TaqMan real-time PCR, sets of primers and probes (Supplementary Table 2 , http://onlinelibrary.wiley.com/doi/10.1002/art.39649/ abstract) were obtained from Applied Biosystems. Samples were run in triplicate using a Step-One Real-Time PCR system (Applied Biosystems). Relative differences in gene expression between controls and patients were determined using the DDC t method as previously described (9) . Final values were expressed as fold induction compared to controls.
Peripheral blood mononuclear cell (PBMC) and synovial fluid mononuclear cell (SFMC) isolation and flow cytometry. PBMCs were obtained as previously described (19) from 5 of the PsA patients in whom ileocolonoscopy was also performed and from 9 additional PsA patients (before and after TNFi treatment in 5 and before and after ustekinumab treatment in 4), 10 AS patients, 10 CD patients, and 10 healthy controls. SFMCs were also obtained from 5 PsA patients who underwent ileocolonoscopy and 5 OA patients. Cell viability (assessed by trypan blue dye exclusion) was always .95%. Four-color flow cytometric analysis was performed using a FACSCalibur (BD Biosciences). At least 50,000 cells (events), gated on lymphocytes or monocyte/macrophage regions, were acquired for each sample. Antibodies used are listed in Supplementary Table 2 (http://onlinelibrary.wiley.com/ doi/10.1002/art.39649/abstract).
Cell cultures. Intestinal epithelial cells were isolated from ileal samples from 5 PsA patients and 5 controls as previously described (20) and cultured in 24-well flat-bottomed plates (Becton Dickinson Labware) at a density of 1 3 10 6 cells in 1 ml RPMI 1640 medium with 10% fetal calf serum, 2 mM L-glutamine, 20 nM HEPES, and 100 units/ml penicillin/ streptomycin with or without recombinant IL-9 (0.1 ng/ml or 10 ng/ml; R&D Systems). Cells were incubated at 378C in a humidified atmosphere containing 5% CO 2 for 48 hours, and levels of IL-17, IL-22, IL-23, retinoic acid receptor2related orphan nuclear receptor, and STAT-3 were then determined by RT-PCR.
Statistical analysis. The statistical significance of differences between groups was calculated by Student's t-test or the nonparametric Mann-Whitney test. Paired samples were analyzed by Wilcoxon's signed rank test. P values less than 0.05 were considered significant. defensin 5, and of the transcription factor SOX9, which is involved in Paneth cell differentiation (21) ( Figures  1L and M) . No differences in the degree of tissue inflammation and/or number of infiltrating cells were observed between patients who were taking nonsteroidal antiinflammatory drugs (NSAIDs) and those who were not (data not shown). Collectively, these data confirm that in patients with PsA, similar to patients with AS, the ileum is characterized by subclinical histologic inflammation.
RESULTS

Subclinical gut inflammation in
Th1 and Th17 polarization in the gut of patients with PsA. We next investigated the expression of cytokines involved in the Th1 and IL-23/Th17 axis. Unlike the findings in CD, and similar to those in AS, Th1 cytokines were not significantly overexpressed in PsA (Figures 2A-C IL-9 overexpression and Th9 polarization in the gut of patients with PsA. We next aimed to investigate in more detail the dominant cytokine pathways involved in subclinical gut inflammation in PsA. Based on recent reports indicating a key role of IL-9 in the pathogenesis of psoriasis (6, 22) , we studied the expression of IL-9 and Th9 in the gut of PsA patients. We first assessed ileal biopsy specimens by RT-PCR for IL-9 and Th9-related transcription factor mRNA expression. Levels of IL-9, PU.1, and interferon regulatory factor 4 mRNA were significantly up-regulated in the gut of PsA patients, especially in those with stage 2-3 lesions, but not in the gut of CD patients, AS patients, or controls ( Figures 3A-C) . In order to confirm IL-9 mRNA expression, paraffin sections of ileal specimens from patients and controls were stained with anti-IL-9 antibody. IL-9 immunoreactivity was observed among infiltrating mononuclear cells (Figures 3D-F) , high endothelial venules ( Figure 3F) , and epithelial cells Figures 3D and E) . IL-9 immunostaining was also observed in ileal biopsy specimens from patients with AS ( Figure 3G ) and CD ( Figure 3H ) and healthy controls ( Figure 3I ), albeit at a much lesser degree. Quantification of the immunostaining confirmed increased IL-9 staining in PsA patients versus controls (P , 0.0001), with a similar trend in patients with CD (P , 0.05), but not in those with AS ( Figure 3K and Supplementary Table 3 Figures 4H-J) . Paneth cells were also demonstrated to overexpress IL-9 in PsA patients, by colocalization of IL-9 and a-defensin 5 ( Figures 4K-M) . Because the functional role of IL-9 depends on the expression of IL-9 receptor (IL-9R), we next studied the expression and tissue distribution of IL-9R. Significantly increased IL-9R expression was observed, at both the mRNA level ( Figure 5A ) and the protein level (Figures 5B2H and J  and Supplementary Table 3 , http://onlinelibrary.wiley. com/doi/10.1002/art.39649/abstract) in the gut of PsA patients compared to healthy controls, patients with AS, and patients with CD. Three main patterns of expression were observed: on the surface of infiltrating inflammatory mononuclear cells ( Figures 5E and F) , among intraepithelial lymphocytes ( Figure 5G) , and in the context of epithelial cells located at the bottom of intestinal crypts, resembling Paneth cells ( Figure 5H ).
To assess the potential functional consequences of increased IL-9 expression in the gut of PsA patients, IL-9-secreting peripheral blood lymphocytes are expanded in PsA patients, express the gut homing marker a4b7, and correlate with disease activity. We next evaluated the potential of peripheral blood lymphocytes from PsA patients to produce IL-9. As shown in Supplementary Figures 2A2C (http://onlinelibrary. wiley.com/doi/10.1002/art.39649/abstract), IL-9-producing CD41 cells were significantly expanded in the peripheral blood of PsA patients compared to AS and CD patients and healthy controls, and expressed PU.1 and a4b7. Their levels were significantly correlated with disease activity as assessed by the BASDAI and DAS28 (Supplementary Figure 2D ). Although differences in the frequency of Th9 cells among patients with systemic lupus erythematosus have been reported to be sex-dependent (23), we observed no difference between male and female patients with PsA (0.85% in female patients versus 0.81% in male patients; P 5 0.8) (data not shown). We also found that a significantly increased proportion of peripheral Th9 cells from PsA patients expressed a4b7 integrin (28% in PsA patients versus 4% in controls; P , 0.05) (Supplementary Figure 2C) , suggesting a gut origin of circulating IL-9-expressing cells in PsA.
IL-9 and IL-9R expression and Th9 cells in PsA synovial samples. Since synovial tissue is one of the main targets of inflammation in PsA, we performed immunohistochemistry analysis to evaluate the expression of IL-9 and IL-9R in synovial fluid and synovial tissue specimens from PsA patients and controls. IL-9 and IL-9R were strongly expressed in the samples from PsA patients ( Figures 6A and B) and observed rarely in samples from patients with OA ( Figure 6C ). IL-9 was observed in leukocytic infiltrates and in the synovial lining layer in patients with PsA, and mainly expressed in the synovial lining layer and among synovial vessels in patients with OA. Semiquantitative analysis of immuno- histochemistry results revealed significantly higher expression of IL-9 in the synovium of patients with PsA compared to that of patients with OA ( Figure 6E and Supplementary Table 3 , http://onlinelibrary.wiley.com/ doi/10.1002/art.39649/abstract). Expression of IL-9 by T cells was confirmed by confocal microscopy analysis ( Figure 6F ), demonstrating that Th9 cells are a source of IL-9 in PsA synovium. IL-9R was also overexpressed in leukocytic infiltrates and in the lining layer of PsA synovium and rarely observed in samples from patients with OA ( Figures 6G-J and Supplementary Table 3) . Flow cytometric analysis demonstrated that Th9 cells were significantly expanded in the synovial fluid of patients with PsA compared to that of patients with OA, and significantly overexpressed a4b7 (Figures 6L-O) .
Effects of TNFi and ustekinumab on circulating Th9 cells. TNFi treatment, and more recently, IL-23 inhibition, have been demonstrated to reduce inflammation in PsA (24) . Nine of the 25 PsA patients enrolled in this study were treated with golimumab (a TNFi) (n 5 5) or ustekinumab (n 5 4), and the frequency of circulating Th9 cells was reassessed after treatment had been initiated. At baseline, 2 patients in the TNFi group and 1 patient in the ustekinumab group did not exhibit macroscopic alterations on ileocolonoscopy. As shown in Supplementary Figure 3 
DISCUSSION
In this study, we confirmed the occurrence of subclinical gut inflammation in PsA patients and provide the first evidence of a specific histologic and immunologic signature characterized by pronounced Paneth cell hyperplasia with fully developed Th17 and Th9 responses. The latter was specific to PsA compared to AS and CD. We also demonstrated that IL-9 overexpression and Th9 polarization occur in inflamed synovial tissue and in the peripheral blood of PsA patients, leading us to hypothesize that there is a link between intestinal and synovial inflammation. Finally, clinical amelioration after treatment with TNFi and ustekinumab was associated with a significant reduction in circulating Th9 cells.
The presence of gut inflammation has been previously demonstrated in the ileal and colonic mucosa of patients with PsA without bowel symptoms, especially in those with axial involvement, even when mucosa appeared macroscopically normal (17, 25, 26) . However, since in AS significant immune alterations were mainly found, in earlier studies, at the ileal level (27) , we focused our attention only on the ileal tract. In our study, both patients with axial involvement and those with peripheral involvement displayed subclinical ileal inflammation, with a higher frequency than that described in previous reports and with similar distribution between axial and peripheral disease.
Eight PsA patients and 3 AS patients in our study were taking NSAIDs at the time of ileocolonoscopy. NSAID-associated ileitis has been described in a significant proportion of long-term NSAIDs users. Histologically, however, it is not easy to distinguish between NSAID-associated ileitis and CD or AS-associated gut inflammation. It has been reported that a type of stricture known as "diaphragm disease" is pathognomonic for NSAID-induced damage (28) . We obviously cannot exclude the possibility that the PsA and AS patients who were taking NSAIDs had NSAID-related ileitis, although no stricture were observed in any of the patients. PsA patients enrolled in our study had high PASI scores and a relatively short duration of disease (;40 months in our study, compared to 40 years in the Belgian study [17] ). The proportion of PsA patients with axial involvement displaying ileal subclinical inflammation was comparable to that in patients with AS. Unlike in AS, however, PsA gut inflammation was characterized by higher numbers of infiltrating inflammatory cells, frequently organized in lymphoid follicles, at levels similar to those observed in patients with CD.
An increased number of Paneth cells was also observed in PsA patients. Paneth cells are highly specialized epithelial cells of the small intestine that reside at the base of small intestinal crypts involved in the synthesis and secretion of antimicrobial peptides required for maintenance of crypt sterility and regulation of the balance of colonizing microbiota and enteric pathogens (29) . Paneth cells originate from the stem cell zone located in the lower portion of the crypt of Lieberk€ uhn, and their differentiation/hyperplasia seem to be dependent on proinflammatory cytokines such as colonystimulating factor 1 (30), IL-9, and IL-13 (31), highlighting the role of inflammation in modulating Paneth cell differentiation. On the other hand, Paneth cells have been also demonstrated to participate in the regulation of several pathways of innate and adaptive immunity, including that of the IL-23/IL-17 axis (27, 32) . The presence of significant intestinal dysbiosis, different from AS dysbiosis (33) , was recently demonstrated in PsA patients (34) . In this context, the increased number of Paneth cells and the increased levels of antimicrobial peptides, such as a-defensin 5, demonstrated in the present study may suggest the activation of innate defensive IL-9 IN PsAresponses in the PsA gut in response to intestinal dysbiosis.
Our immunologic characterization of the inflamed gut of PsA patients demonstrated a distinctive constellation of immune responses. Similar to previous findings in AS (27) , we did not observe significant upregulation of Th1-related cytokines. On the other hand, different from findings in AS and similar to those in CD, a fully developed Th17 response, characterized by strong up-regulation of both IL-17 and IL-22, appears to be present in the gut of patients with PsA.
Beyond the IL-23/Th17 axis, however, a newly recognized subset of effector T cells-so-called Th9 cells-has been suggested to play a role in the pathogenesis of human inflammatory diseases, and in particular, psoriasis (35) . Although Th9 cells have been shown to be involved in the pathogenesis of psoriasis, their developmental origin remains elusive (6, 22) . In this study we demonstrated for the first time that IL-9 is strongly overexpressed by infiltrating inflammatory cells in the gut of patients with PsA. Among inflammatory cells, Th9 lymphocytes were the major source of IL-9 in PsA, highlighting the role of adaptive immunity in the production of IL-9. Of note, IL-9 was also produced by Paneth cells, and these cells also expressed IL-9R. These data, together with the evidence that stimulation of epithelial cells with IL-9 up-regulates the expression of antimicrobial peptides and of cytokines, such as IL-23, may also suggest the possibility of a functional autocrine loop involving IL-9/IL-9R.
Both peripheral arthritis and spine inflammation occur in patients with PsA. We therefore also evaluated PsA synovial samples for IL-9 and IL-9R expression, and demonstrated that both were significantly overexpressed. In PsA synovial tissue synovial fibroblasts and synovial vessels, together with Th9 cells, were found to be the main source of IL-9. Constitutive production of IL-9 was also observed in OA synovial samples, in which endothelial cells and synovial fibroblasts were demonstrated to produce IL-9.
Th9 cells were also expanded in the peripheral blood and synovial fluid of PsA patients, and their levels were correlated with disease activity. The relatively low percentage of circulating Th9 cells (although significantly increased compared to controls) was similar to that described in other autoimmune diseases (36) , indicating that these cells probably specifically recirculate at sites of inflammation. Notably, both circulating and synovial Th9 cells expressed relatively high levels of the intestinal homing receptor a4b7, suggesting a predominant intestinal origin of these cells. Although only a small number of PsA patients were studied before and after biologic treatment, in both TNFi-and ustekinumabtreated patients we observed a significant reduction of circulating Th9 cells occurring together with clinical improvement.
In conclusion, specific histologic and immunologic features seem to characterize the subclinical gut inflammation in patients with PsA. We also demonstrated that Th1 is predominant in CD but not in spondyloarthritis (AS and PsA), that Th17/22 expression is increased in all 3 diseases, and most importantly, that only Th9 cells are specific to PsA. These findings suggest that IL-9 and Th9 cells may play a role in driving local and systemic inflammation in PsA and might be considered as a potential future therapeutic target.
